Volrustomig Phase III NSCLC Failure Exposes Bispecific Checkpoint Format Risk Across Remaining Indications

AstraZeneca's Volrustomig Fails Phase III NSCLC Trial

AstraZeneca has experienced a significant setback with the failure of its PD-1 bispecific antibody, volrustomig, in a Phase III clinical trial for non-small cell lung cancer (NSCLC). This outcome is considered a major blow to the company's ambitions to lead in the development of PD-1-based bispecific antibodies for solid tumors in Western markets. Despite this specific failure, AstraZeneca is continuing to evaluate volrustomig in other indications, including cervical cancer, renal cell carcinoma, mesothelioma, head and neck squamous cell carcinoma, and other NSCLC patient segments.

• Phase III Failure in NSCLC: AstraZeneca's PD-1 bispecific antibody, volrustomig, failed to meet its primary endpoints in a Phase III trial for non-small cell lung cancer. This represents a significant clinical setback for the drug's development in this specific indication.
• Impact on Market Ambitions: The failure is a major blow to AstraZeneca's strategic goal of establishing leadership in the emerging market for PD-1-based bispecific antibodies targeting solid tumors, particularly within Western markets. This outcome could influence its competitive positioning against other developers in this therapeutic space.
• Ongoing Development in Other Indications: Despite the NSCLC Phase III failure, AstraZeneca is actively continuing the clinical development of volrustomig across a range of other cancer types. These include ongoing trials in cervical cancer, renal cell carcinoma, mesothelioma, head and neck squamous cell carcinoma, and additional patient segments within NSCLC, indicating a broader development strategy for the drug.

Addressing Persistent Challenges in NSCLC Treatment

Despite meaningful advances in targeted therapy and immunotherapy, NSCLC remains a disease with substantial unmet need, driven by complex resistance mechanisms, limited late-line options, and inadequate predictive biomarkers. The 5-year overall survival rate remains below 20%, with most patients presenting at advanced stage and real-world second-line median overall survival falling below 7 months.

• Acquired resistance to EGFR-targeted therapies: Most patients treated with first- or second-generation EGFR TKIs (erlotinib, gefitinib, afatinib) inevitably develop acquired resistance, with the T790M mutation accounting for approximately 50% of resistance subtypes. While osimertinib addresses T790M-mediated resistance, the C797S mutation emerges as the primary acquired resistance mechanism against this third-generation agent. No fourth-generation TKI targeting C797S has yet received clinical approval. Additional resistance mechanisms — including HER2 and MET amplification, PIK3A, KRAS, and BRAF mutations, and histological transformation to small cell lung cancer or squamous cell carcinoma — are observed at relatively high frequency, yet actionable treatment options remain limited.

• Immunotherapy resistance: The majority of patients derive limited long-term benefit from immune checkpoint inhibition due to primary or acquired resistance. Mutations in KEAP1, SMARCA4, and PTEN drive immune evasion independently of PD-L1 expression or tumor mutational burden, with co-occurrence alongside KRAS and STK11 mutations further compounding resistance. Additionally, cancer cell–selective TAP2 protein downregulation — present in 42.4% of treatment-naïve NSCLCs and mediated by IL-4 signaling — represents a distinct dominant mechanism of immune evasion that diminishes sensitivity to checkpoint blockade.

• Biomarker limitations: Clinically established predictive biomarkers, including PD-L1 expression and tumor mutational burden, have well-recognized limitations in reliably stratifying patients for immunotherapy. Liquid biopsy, while enabling surveillance of EGFR mutational status across the full genetic landscape, carries a considerable false-negative rate for plasma-based detection, rendering tissue biopsy indispensable in many clinical scenarios.

• Restricted options for rare oncogenic drivers and later lines of therapy: Patients harboring druggable rare alterations — including KRAS G12C, MET exon 14 skipping, HER2 exon 20 insertion, BRAF V600E, and ROS1/RET rearrangements — face limited therapeutic choices, and real-world efficacy outcomes for targeted agents such as MET inhibitors fall short of those reported in prospective trials. Beyond second line, treatment options narrow considerably, with available modalities largely confined to platinum-based chemotherapy, driver-mutation–directed therapy, and immune checkpoint inhibitors.

• Uncertainties in combination strategies: Although combinations of EGFR TKIs with chemotherapy or other targeted agents have demonstrated survival benefit in some resistant settings, the evidence base remains controversial. Novel combination approaches, such as navarixin plus pembrolizumab, have failed to demonstrate sufficient efficacy in phase 2 evaluation, underscoring the difficulty of translating mechanistic rationale into clinical benefit.

Navigating the Crowded PD-1 Bispecific Landscape in NSCLC

The PD-1/CTLA-4 bispecific antibody class is among the most actively investigated mechanisms in oncology, with volrustomig competing alongside several co-targeting agents in the clinical pipeline. Dual PD-1/CTLA-4 inhibitors collectively account for the highest number of bispecific antibody trials in solid tumors (n = 208; 30.5%), underscoring the intensity of activity in this space. Among randomized clinical trials evaluating bispecific antibodies in solid tumors, parallel assignment is the predominant intervention model, used in 12 trials, with crossover assignment employed in 1 trial and intervention models unreported in 2 trials.

Volrustomig's NSCLC Setback: A Strategic Pivot for Bispecifics

AstraZeneca's recent announcement regarding the Phase III failure of its PD-1 bispecific antibody, volrustomig, in non-small cell lung cancer (NSCLC) marks a significant moment for the company and the broader immuno-oncology field. Volrustomig, also known as MEDI5752, was engineered with a unique design: a monovalent bispecific antibody intended to preferentially target CTLA-4 on PD-1-positive T cells while maintaining robust PD-1 inhibition. This 'rational design' aimed to improve upon existing dual checkpoint blockade strategies by potentially enhancing efficacy and modulating immune-related adverse events.

Early clinical data for volrustomig as a monotherapy showed encouraging signs, with an objective response rate of nearly 20% and a median response duration of 17.5 months in advanced cancer patients. However, the Phase III setback in NSCLC highlights the formidable challenges in treating this complex disease. The NSCLC landscape is highly competitive and rapidly evolving, with studies demonstrating the limited efficacy of older second-line treatments like erlotinib in unselected patients, and a clear trend towards biomarker-directed combination therapies, such as pembrolizumab with lenvatinib or other immune checkpoint inhibitors.

For AstraZeneca, this outcome is a blow to its ambitions in PD-1-based bispecifics for solid tumors. However, the company's decision to continue evaluating volrustomig in other indications—including cervical cancer, renal cell carcinoma, mesothelioma, and head and neck squamous cell carcinoma—suggests a strategic pivot. This move indicates a belief that the drug's unique mechanism may still hold promise in different tumor microenvironments or patient populations where the risk-benefit profile could be more favorable. The high rate of treatment-related adverse events observed in early studies, leading to discontinuation in over a third of patients, remains a critical consideration for its broader utility. The future of volrustomig will now hinge on its performance in these alternative indications, potentially with more refined patient selection strategies to unlock its full therapeutic potential.